Medical School · Year 3 · Neurology · includes a quiz and discussion video

Seminar 04: Epilepsy and Seizures

Year 3: Neurology Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Classify seizure types and epilepsy syndromes
2. Differentiate epileptic seizures from mimics
3. Evaluate a patient with first-time seizure
4. Apply antiseizure medication principles
5. Manage status epilepticus
6. Counsel patients on epilepsy-related issues

Seminar Outline

I. Definitions and Classification

Understanding the fundamental terminology in epilepsy provides the foundation for accurate diagnosis and appropriate management. A seizure represents a transient occurrence of signs and symptoms resulting from abnormal, excessive, or synchronous neuronal activity in the brain. This definition emphasizes the paroxysmal nature of seizures and their basis in pathological electrical discharges. Epilepsy, in contrast, is defined as the occurrence of at least two unprovoked seizures separated by more than twenty-four hours, or alternatively, a single unprovoked seizure in the context of a high recurrence risk exceeding sixty percent. This diagnostic framework recognizes that epilepsy represents an enduring predisposition to generate seizures rather than an isolated event.

The distinction between provoked and unprovoked seizures carries significant implications for prognosis and treatment decisions. Provoked seizures occur in the setting of an acute precipitating factor such as alcohol withdrawal, metabolic derangements including severe hypoglycemia or hyponatremia, acute intoxication, or systemic illness with fever. These acute symptomatic seizures generally carry a lower risk of recurrence once the precipitating factor has been addressed and typically do not warrant long-term antiseizure medication therapy. Status epilepticus represents a neurological emergency defined as a seizure lasting longer than five minutes or the occurrence of two or more seizures without full recovery of consciousness between episodes.

The International League Against Epilepsy 2017 classification system organizes seizures based on their onset characteristics. Seizures are classified as focal onset when they originate within networks limited to one hemisphere, generalized onset when they engage bilateral hemispheric networks from the beginning, or unknown onset when insufficient information exists to categorize the initial manifestations. Focal seizures are further subdivided based on whether awareness is preserved or impaired during the episode. A focal seizure with retained awareness indicates that the patient remains conscious and oriented throughout, while focal with impaired awareness denotes altered consciousness during the event.

Generalized seizures encompass several distinct seizure types with characteristic clinical and electroencephalographic features. Motor manifestations include tonic-clonic seizures with bilateral stiffening followed by rhythmic jerking, myoclonic seizures characterized by brief shock-like jerks, tonic seizures with sustained bilateral stiffening, atonic seizures producing sudden loss of muscle tone, and clonic seizures featuring rhythmic jerking movements. Non-motor generalized seizures include absence seizures presenting as brief episodes of behavioral arrest and unresponsiveness. The category of focal to bilateral tonic-clonic describes seizures that begin with focal onset and then evolve to engage bilateral hemispheric networks.

<image>Panel A: Diagram illustrating seizure classification hierarchy showing focal, generalized, and unknown onset categories with subcategories. Panel B: EEG tracing demonstrating characteristic spike-wave patterns for different seizure types. Panel C: Brain illustration showing focal seizure onset in temporal lobe versus generalized bilateral involvement. Panel D: Timeline comparing provoked versus unprovoked seizure contexts and their diagnostic implications.</image>

II. Epilepsy Syndromes

Epilepsy syndromes represent constellations of clinical features including seizure types, age of onset, electroencephalographic patterns, associated neurological findings, and etiologies that together define recognizable clinical entities with prognostic and therapeutic implications. Childhood absence epilepsy typically presents between four and ten years of age with brief staring spells lasting seconds, accompanied by three-hertz spike-wave discharges on electroencephalography that can be provoked by hyperventilation. This syndrome frequently remits spontaneously by adolescence, offering families reassurance about long-term prognosis. Juvenile myoclonic epilepsy emerges during adolescence with the characteristic triad of myoclonic jerks predominantly occurring in the morning upon awakening, generalized tonic-clonic seizures, and occasionally absence seizures.

Benign rolandic epilepsy, also known as childhood epilepsy with centrotemporal spikes, presents between three and thirteen years of age with focal motor seizures involving the face and oropharyngeal muscles, often occurring during sleep or upon awakening. The characteristic electroencephalographic pattern demonstrates centrotemporal spikes that are activated by drowsiness and sleep. This syndrome carries an excellent prognosis with seizures typically remitting by adolescence, and many patients do not require treatment. Lennox-Gastaut syndrome represents the severe end of the spectrum, presenting in early childhood with multiple seizure types including tonic, atonic, and atypical absence seizures accompanied by cognitive impairment and a characteristic slow spike-wave pattern on electroencephalography.

Juvenile myoclonic epilepsy deserves particular attention as one of the most common genetic generalized epilepsy syndromes encountered in clinical practice. The syndrome typically manifests between twelve and eighteen years of age with myoclonic jerks that patients often describe as clumsiness or dropping objects, particularly in the morning. These myoclonic seizures are characteristically provoked by sleep deprivation, alcohol consumption, and photic stimulation. The electroencephalogram demonstrates four to six hertz polyspike-wave discharges, often with a photoparoxysmal response. While seizures respond well to appropriate medications, patients typically require lifelong treatment as the condition does not remit.

Temporal lobe epilepsy represents the most common form of adult focal epilepsy and often develops in the context of mesial temporal sclerosis, a pathological process involving hippocampal neuronal loss and gliosis. Patients characteristically experience an aura consisting of a rising epigastric sensation, feelings of deja vu or jamais vu, fear, or olfactory hallucinations preceding seizures with impaired awareness. During the seizure, patients display behavioral arrest followed by oral and manual automatisms such as lip smacking, chewing movements, and fumbling with objects. Temporal lobe epilepsy often proves refractory to medication, and surgical resection of the epileptogenic temporal lobe offers the possibility of seizure freedom in carefully selected candidates with concordant localization data.

<image>Panel A: Age-of-onset timeline showing typical presentation ages for childhood absence, juvenile myoclonic, benign rolandic, and temporal lobe epilepsy. Panel B: EEG examples demonstrating three-hertz spike-wave in absence epilepsy versus polyspike-wave in JME versus centrotemporal spikes in rolandic epilepsy. Panel C: MRI image showing hippocampal sclerosis with volume loss and signal change in temporal lobe epilepsy. Panel D: Prognosis comparison chart showing remission rates and treatment requirements for different epilepsy syndromes.</image>

III. First Seizure Evaluation

The evaluation of a patient presenting with a first seizure requires systematic assessment to establish the diagnosis, identify potential etiologies, and estimate recurrence risk to guide treatment decisions. History taking represents the cornerstone of evaluation and should incorporate detailed accounts from witnesses whenever possible. The clinician must reconstruct the sequence of events including any warning symptoms or aura, the patient's activity and position at onset, the evolution of motor manifestations, the duration of the episode, and the pattern of recovery. Particular attention should focus on features that might suggest alternative diagnoses such as triggers consistent with syncope, prolonged duration suggesting psychogenic events, or symptoms suggesting metabolic or toxic precipitants.

Distinguishing epileptic seizures from syncope represents one of the most common diagnostic challenges in the evaluation of transient loss of consciousness. Syncope typically occurs in the context of identifiable triggers such as prolonged standing, pain, emotional stress, or heat exposure, while seizures often occur without warning from any body position. The duration of unconsciousness in syncope rarely exceeds one minute, whereas tonic-clonic seizures typically last one to two minutes. Motor manifestations in syncope, when present, consist of brief myoclonic jerks that are irregular and less sustained than the rhythmic jerking of a seizure. Eye position during the event provides valuable information, with eyes typically open and deviated during seizures but closed or rolling in syncope.

The diagnostic evaluation following a first unprovoked seizure includes laboratory testing, neuroimaging, and electroencephalography. Initial laboratory studies should assess for metabolic derangements including blood glucose, serum sodium, calcium, and magnesium, as well as toxicology screening when substance use is suspected. Electroencephalography yields epileptiform abnormalities in approximately thirty percent of patients after a first unprovoked seizure, increasing to fifty percent with sleep deprivation or prolonged recording. Magnetic resonance imaging of the brain with epilepsy protocol sequences should be obtained to identify structural lesions including hippocampal sclerosis, cortical dysplasia, tumors, vascular malformations, or evidence of prior stroke or trauma.

Risk stratification following a first unprovoked seizure guides decisions about antiseizure medication initiation. The overall risk of seizure recurrence after a single unprovoked seizure is approximately forty percent over two years, but this risk varies substantially based on individual factors. Abnormalities on electroencephalography, particularly epileptiform discharges, significantly increase recurrence risk, as do structural lesions on neuroimaging. Nocturnal seizures carry higher recurrence rates than those occurring during wakefulness. Patients presenting in status epilepticus or with known prior neurological injury such as stroke or traumatic brain injury also face elevated recurrence risk. When recurrence risk exceeds sixty percent based on these factors, initiating treatment after a single seizure may be appropriate.

<image>Panel A: Comparison table contrasting clinical features of epileptic seizures versus syncope including onset, duration, motor features, eye position, and recovery. Panel B: Flowchart for first seizure evaluation showing history, examination, laboratory, EEG, and imaging workup. Panel C: Graph illustrating seizure recurrence risk over time with and without identified risk factors. Panel D: Decision algorithm for antiseizure medication initiation following first unprovoked seizure.</image>

IV. Differential Diagnosis

The differential diagnosis of seizures encompasses a broad range of conditions that can mimic epileptic events, and accurate diagnosis is essential to avoid inappropriate treatment and ensure appropriate management. Psychogenic non-epileptic seizures represent one of the most important mimics, accounting for a significant proportion of patients referred to epilepsy monitoring units. These events arise from psychological processes rather than abnormal electrical activity and require fundamentally different treatment approaches. Clinical features suggesting psychogenic non-epileptic seizures include gradual onset rather than abrupt, prolonged duration often exceeding two minutes, variable and waxing-waning motor manifestations, eyes closed during the event, relative preservation from injury, and rapid return to alertness without typical postictal confusion.

Syncope remains the most common alternative diagnosis considered when evaluating paroxysmal events with loss of consciousness. The pathophysiology involves transient global cerebral hypoperfusion from various mechanisms including vasovagal responses, orthostatic hypotension, or cardiac arrhythmias. Convulsive syncope occurs when hypoperfusion triggers brief myoclonic activity, potentially leading to misdiagnosis as epileptic seizure. Key distinguishing features include identifiable triggers, premonitory symptoms of lightheadedness and tunnel vision, pallor and diaphoresis during the event, and rapid recovery of orientation within seconds to minutes. Transient ischemic attacks produce negative symptoms reflecting loss of function in a vascular distribution rather than the positive symptoms and stereotyped progression characteristic of seizures.

Provoked seizures occur in the setting of acute precipitating factors and carry different prognostic and therapeutic implications than unprovoked epileptic seizures. Metabolic causes include severe hypoglycemia typically below forty milligrams per deciliter, hyponatremia particularly when severe or rapidly developing, hypocalcemia, and uremia. Withdrawal states, particularly from alcohol, benzodiazepines, and barbiturates, represent common precipitants in emergency department settings. Drug intoxication with cocaine, amphetamines, or other stimulants can provoke seizures, as can certain medications including tramadol, bupropion, fluoroquinolones, and isoniazid. Acute structural brain insults including stroke within seven days, traumatic brain injury, and central nervous system infections constitute acute symptomatic causes.

Other conditions entering the differential diagnosis include sleep disorders such as parasomnias and narcolepsy with cataplexy, movement disorders including paroxysmal dyskinesias and tics, migraine with aura particularly when manifesting with motor or sensory symptoms, and panic attacks when accompanied by hyperventilation and altered awareness. Detailed history taking focusing on the circumstances, phenomenology, duration, and recovery pattern of events allows accurate differentiation in most cases. When diagnostic uncertainty persists, video-electroencephalographic monitoring during events provides definitive characterization by simultaneously documenting clinical manifestations and the presence or absence of ictal electrographic changes.

<image>Panel A: Clinical features comparison table for epileptic seizure versus PNES versus syncope including onset, duration, movements, eyes, injury, and recovery. Panel B: Metabolic and toxic causes of provoked seizures organized by category with threshold values where applicable. Panel C: Ictal video-EEG example demonstrating normal background during documented clinical event consistent with PNES. Panel D: Algorithm for approaching the differential diagnosis of paroxysmal events with loss of consciousness.</image>

V. Antiseizure Medications: Principles

The selection of antiseizure medications requires consideration of seizure type, epilepsy syndrome, patient-specific factors, and drug characteristics to optimize efficacy while minimizing adverse effects. Understanding mechanisms of action provides insight into the spectrum of activity for different medications. Sodium channel blockers including carbamazepine, phenytoin, oxcarbazepine, and lacosamide reduce neuronal excitability by stabilizing the inactivated state of voltage-gated sodium channels, thereby limiting repetitive high-frequency firing. These agents work primarily against focal seizures and focal to bilateral tonic-clonic seizures but may worsen certain generalized epilepsies. T-type calcium channel blockers including ethosuximide and to some extent valproate specifically target the thalamocortical circuits involved in absence seizures.

Medications enhancing gamma-aminobutyric acid inhibition represent another major mechanism class. Benzodiazepines and barbiturates allosterically modulate GABA-A receptors to increase chloride conductance and neuronal inhibition. Levetiracetam and brivaracetam bind to synaptic vesicle protein 2A, modulating neurotransmitter release through mechanisms not fully characterized. Valproate and topiramate act through multiple mechanisms including sodium channel effects, enhancement of GABAergic inhibition, and in the case of valproate, effects on T-type calcium channels, contributing to their broad-spectrum efficacy across multiple seizure types.

The choice of antiseizure medication should be guided by seizure type and epilepsy syndrome classification. For focal seizures, first-line options include levetiracetam, lamotrigine, and oxcarbazepine, all demonstrating good efficacy with acceptable side effect profiles. Generalized tonic-clonic seizures respond to valproate, levetiracetam, and lamotrigine. Absence seizures require agents with activity against the thalamocortical circuits generating these discharges, with ethosuximide, valproate, and lamotrigine representing first-line choices. Myoclonic seizures respond to valproate and levetiracetam. Importantly, certain medications including carbamazepine, phenytoin, and gabapentin may exacerbate absence and myoclonic seizures and should be avoided in patients with genetic generalized epilepsies.

General principles of antiseizure medication therapy include initiating monotherapy as the initial approach, slowly titrating to therapeutic doses to minimize side effects, ensuring an adequate trial at therapeutic doses before declaring treatment failure, and considering side effect profiles in relation to individual patient characteristics. Therapeutic drug monitoring is useful for medications with narrow therapeutic indices including phenytoin, carbamazepine, and valproate, particularly when assessing compliance, evaluating toxicity, or managing drug interactions. The goal of treatment is complete seizure freedom with acceptable tolerability, achieved in approximately fifty percent of patients with the first medication tried and an additional fifteen to twenty percent with a second or third medication.

<image>Panel A: Mechanism of action diagram showing sodium channel blockers, calcium channel effects, and GABAergic enhancement with representative medications. Panel B: Seizure type to medication matching table showing first-line choices for focal, generalized tonic-clonic, absence, and myoclonic seizures. Panel C: Warning regarding medications that may worsen genetic generalized epilepsies with specific agents to avoid. Panel D: Therapeutic drug level ranges for medications requiring monitoring with interpretation guidelines.</image>

VI. Specific Antiseizure Medications

Levetiracetam has become one of the most widely prescribed antiseizure medications due to its favorable pharmacokinetic profile, broad-spectrum efficacy, and ease of use. The medication binds to synaptic vesicle protein 2A, modulating neurotransmitter release, though the precise mechanism underlying its antiseizure effect remains incompletely understood. Levetiracetam can be initiated at therapeutic doses without the need for gradual titration, simplifying initiation particularly in acute settings. The medication undergoes minimal hepatic metabolism with predominantly renal elimination, resulting in few drug interactions. However, behavioral side effects including irritability, mood changes, and aggression occur in a subset of patients and may necessitate discontinuation or addition of pyridoxine supplementation.

Lamotrigine represents another broad-spectrum antiseizure medication effective against both focal and generalized seizures including absence seizures. The medication acts primarily through sodium channel blockade and also affects voltage-gated calcium channels. A significant advantage of lamotrigine includes its weight neutrality and mood-stabilizing properties, making it particularly suitable for patients concerned about weight gain or those with comorbid mood disorders. However, lamotrigine requires very slow titration over several weeks to minimize the risk of serious cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. This requirement for gradual titration limits its utility in situations requiring rapid seizure control. Drug interactions significantly affect lamotrigine levels, with valproate approximately doubling concentrations.

Valproate possesses the broadest spectrum of activity among antiseizure medications, demonstrating efficacy against focal seizures, generalized tonic-clonic seizures, absence seizures, and myoclonic seizures. The medication acts through multiple mechanisms including sodium channel effects, enhancement of GABAergic inhibition, and T-type calcium channel blockade. Valproate remains a first-line option for genetic generalized epilepsies including juvenile myoclonic epilepsy. However, significant side effects limit its use including weight gain, tremor, hair loss, and hepatotoxicity particularly in young children on polytherapy. Most importantly, valproate is highly teratogenic, causing neural tube defects and other congenital malformations as well as neurodevelopmental impairments in exposed children, and should be avoided in women of childbearing potential whenever alternative options exist.

Other important antiseizure medications each possess distinct characteristics guiding their use. Carbamazepine and oxcarbazepine are effective sodium channel blockers for focal epilepsies but may cause hyponatremia and potentially serious cutaneous reactions, with oxcarbazepine carrying slightly lower risk. Phenytoin remains useful for acute management given availability of intravenous formulation but has a narrow therapeutic index, nonlinear kinetics, multiple drug interactions, and cosmetic side effects limiting long-term use. Topiramate provides broad-spectrum efficacy but cognitive side effects including word-finding difficulty and slowed processing limit tolerability for many patients. Lacosamide offers good tolerability with a novel mechanism enhancing slow inactivation of sodium channels, though PR interval prolongation requires monitoring in patients with cardiac conduction abnormalities.

<image>Panel A: Levetiracetam profile showing mechanism, advantages including no titration and few interactions, and behavioral side effect considerations. Panel B: Lamotrigine titration schedule emphasizing slow introduction to prevent cutaneous reactions, with interaction table for valproate co-administration. Panel C: Valproate efficacy spectrum diagram with prominent teratogenicity warning and recommendations for women of childbearing potential. Panel D: Comparison table of side effect profiles for major antiseizure medications to guide selection based on patient characteristics.</image>

VII. Status Epilepticus

Status epilepticus represents a medical emergency requiring immediate recognition and aggressive management to prevent neuronal injury, systemic complications, and death. The operational definition of convulsive status epilepticus has evolved from the traditional thirty minutes to the current five-minute threshold, reflecting evidence that seizures failing to terminate spontaneously within five minutes rarely self-terminate and that earlier treatment improves outcomes. Non-convulsive status epilepticus describes a state of altered awareness or behavior associated with ongoing electrographic seizure activity without prominent motor manifestations and requires electroencephalography for diagnosis. Refractory status epilepticus is defined as seizures persisting despite treatment with benzodiazepines and at least one appropriately dosed second-line agent.

The etiologies of status epilepticus are diverse and their identification guides management beyond seizure termination. In patients with established epilepsy, medication non-adherence or subtherapeutic antiseizure medication levels represent the most common precipitants. Acute brain injuries including stroke, traumatic brain injury, and central nervous system infections frequently manifest with status epilepticus. Metabolic derangements including severe hypoglycemia, hyponatremia, and uremia can trigger prolonged seizures. Toxic and withdrawal states, particularly alcohol withdrawal, require specific consideration. Autoimmune encephalitides including anti-NMDA receptor encephalitis represent an increasingly recognized cause, particularly in young patients with new-onset refractory status epilepticus, and require early immunotherapy alongside antiseizure treatment.

The management of convulsive status epilepticus follows a time-based protocol emphasizing rapid escalation of therapy. During the initial stabilization phase within the first five minutes, attention focuses on airway protection, establishing intravenous access, checking glucose, and obtaining laboratory studies including antiseizure medication levels when applicable. First-line treatment consists of benzodiazepines, with intravenous lorazepam at four milligrams being the preferred agent when intravenous access is available. When intravenous access cannot be established rapidly, intramuscular midazolam at ten milligrams provides equivalent efficacy with faster administration. If seizures persist after adequate benzodiazepine dosing, second-line agents including fosphenytoin, valproate, or levetiracetam should be administered intravenously at appropriate loading doses.

Refractory status epilepticus persisting despite benzodiazepines and a second-line agent requires intensive care unit admission and consideration of continuous intravenous anesthetic infusions. Propofol and midazolam infusions represent first-line options for anesthetic management, titrated to achieve seizure suppression or burst suppression on continuous electroencephalographic monitoring. Pentobarbital provides an alternative for cases refractory to initial anesthetic agents. Patients require intubation and mechanical ventilation during anesthetic treatment, with careful attention to hemodynamic support as these agents frequently cause hypotension. The optimal duration of anesthetic treatment and rate of weaning remain subjects of ongoing study, but generally treatment continues for twenty-four to forty-eight hours of seizure suppression before gradual withdrawal while monitoring for recurrence.

<image>Panel A: Status epilepticus definition diagram showing five-minute threshold and relationship between seizure duration and spontaneous termination probability. Panel B: Time-based treatment protocol flowchart showing stabilization, first-line benzodiazepines, second-line agents, and progression to anesthetic therapy. Panel C: Medication dosing table for status epilepticus including lorazepam, midazolam, fosphenytoin, valproate, and levetiracetam with routes and doses. Panel D: Continuous EEG monitoring example showing burst suppression pattern during anesthetic treatment of refractory status epilepticus.</image>

VIII. Drug-Resistant Epilepsy

Drug-resistant epilepsy is defined as the failure to achieve sustained seizure freedom after adequate trials of two appropriately chosen, tolerated, and appropriately dosed antiseizure medication schedules, whether as monotherapy or in combination. This definition applies to approximately thirty percent of patients with epilepsy, representing a significant population requiring evaluation for alternative therapeutic approaches. The recognition of drug resistance should prompt referral to a comprehensive epilepsy center for detailed evaluation including video-electroencephalographic monitoring, high-resolution magnetic resonance imaging, and assessment of surgical candidacy. Early recognition and referral are important as prolonged uncontrolled seizures carry risks of injury, cognitive decline, psychosocial impairment, and sudden unexpected death in epilepsy.

Epilepsy surgery offers the potential for seizure freedom in carefully selected candidates with identifiable seizure foci amenable to resection. Temporal lobectomy for mesial temporal sclerosis represents the best-established surgical procedure, with sixty to eighty percent of patients achieving seizure freedom. The presurgical evaluation process aims to localize the seizure onset zone and determine whether resection can be accomplished without unacceptable neurological deficits. This evaluation integrates data from video-electroencephalographic monitoring capturing typical seizures, high-resolution structural imaging, functional imaging including positron emission tomography and ictal single-photon emission computed tomography, neuropsychological testing, and when necessary invasive monitoring with intracranial electrodes. Corpus callosotomy represents a palliative disconnection procedure primarily indicated for drop attacks in patients with frequent atonic or tonic seizures.

Neuromodulation devices provide options for patients who are not surgical candidates or who have failed resective surgery. Vagus nerve stimulation involves implantation of a pulse generator delivering intermittent electrical stimulation to the left vagus nerve, resulting in modest seizure reduction in the range of thirty to fifty percent for most patients. Responsive neurostimulation represents a more recently approved technology in which intracranial electrodes detect electrographic seizure patterns and deliver targeted stimulation to abort seizures before clinical manifestation. Deep brain stimulation targeting the anterior nucleus of the thalamus has demonstrated efficacy in reducing seizure frequency in patients with drug-resistant focal epilepsy. These devices generally provide seizure reduction rather than seizure freedom, with improvements often continuing over years of therapy.

Dietary therapies represent additional options for drug-resistant epilepsy, particularly in pediatric populations. The ketogenic diet, consisting of high fat, adequate protein, and very low carbohydrate intake to induce ketosis, demonstrates efficacy comparable to adding a new antiseizure medication, with approximately half of patients experiencing greater than fifty percent seizure reduction. The diet requires careful nutritional supervision and monitoring but may be particularly effective for certain epilepsy syndromes including infantile spasms, Dravet syndrome, and glucose transporter type one deficiency. The modified Atkins diet and low glycemic index treatment offer less restrictive alternatives with somewhat lower efficacy. Immunotherapy may benefit patients with autoimmune etiologies identified through antibody testing or clinical features suggesting immune-mediated disease.

<image>Panel A: Definition and prevalence of drug-resistant epilepsy with criteria for diagnosis and indications for epilepsy center referral. Panel B: Presurgical evaluation components diagram showing video-EEG, MRI, PET, neuropsychology, and invasive monitoring integration. Panel C: Neuromodulation device comparison showing VNS, RNS, and DBS mechanisms, targets, and expected outcomes. Panel D: Dietary therapy options comparison showing ketogenic diet, modified Atkins, and low glycemic index treatment with efficacy and practical considerations.</image>

IX. Special Considerations

Management of epilepsy in women of childbearing potential requires careful attention to the teratogenic potential of antiseizure medications and the complex interactions between hormones, seizures, and medications. Preconception counseling represents a critical opportunity to optimize medication regimens, minimize teratogenic exposure, and ensure appropriate folate supplementation. Valproate carries the highest teratogenic risk among commonly used antiseizure medications, causing neural tube defects in approximately ten percent of exposed pregnancies and associated with reduced cognitive outcomes in children, making it a medication to avoid in this population whenever possible. Enzyme-inducing antiseizure medications including carbamazepine, phenytoin, and phenobarbital reduce the efficacy of hormonal contraception, requiring higher-dose formulations or alternative contraceptive methods.

Driving regulations for patients with epilepsy vary by jurisdiction but generally require a seizure-free interval ranging from three to twelve months before driving is permitted. Physicians have varying legal obligations regarding reporting, and clear documentation of counseling regarding driving restrictions is essential. Employment considerations include restrictions from occupations involving heights, heavy machinery operation, or commercial driving. Patients should be counseled regarding safety precautions including avoiding swimming alone, taking showers rather than baths, and using common-sense measures around fire and heights. Alcohol should be used with caution given its seizure-provoking potential and interactions with antiseizure medications.

Sudden unexpected death in epilepsy represents a devastating complication accounting for significant mortality in patients with uncontrolled seizures. The incidence approximates one per one thousand patient-years in the general epilepsy population but rises substantially higher in patients with drug-resistant epilepsy and frequent generalized tonic-clonic seizures. The mechanism is incompletely understood but likely involves postictal respiratory dysfunction, cardiac arrhythmias, or both, particularly in the context of nocturnal seizures without supervision. Risk factors include frequent generalized tonic-clonic seizures, nocturnal seizures, young age, and long duration of epilepsy. The most effective prevention strategy is achieving seizure control, with nighttime supervision and seizure monitoring devices offering potential additional benefit.

Medication withdrawal may be considered in patients who have achieved sustained seizure freedom, typically defined as at least two years without seizures while on medication. Factors favoring successful withdrawal include normal electroencephalogram, normal neuroimaging, and a syndrome with known tendency toward remission such as childhood absence epilepsy or benign rolandic epilepsy. Even under favorable circumstances, approximately thirty to forty percent of patients experience seizure recurrence during or after medication withdrawal, typically within the first year. The decision to attempt withdrawal requires careful discussion of risks including recurrence with potential driving implications, balanced against the benefits of avoiding long-term medication effects. Withdrawal should be gradual, typically over several months, with clear counseling regarding signs of recurrence.

<image>Panel A: Pregnancy and epilepsy management flowchart showing preconception counseling, teratogenicity comparison, folate supplementation, and monitoring during pregnancy. Panel B: Driving regulations summary with typical seizure-free intervals and physician reporting requirements by jurisdiction. Panel C: SUDEP risk factors diagram with relative risk magnitudes and prevention strategies. Panel D: Medication withdrawal consideration algorithm showing favorable factors, expected outcomes, and gradual tapering approach.</image>

X. Acute Seizure Management

The appropriate response to witnessing a seizure focuses on protecting the patient from injury while allowing the seizure to run its course and carefully observing the event characteristics. Bystanders should clear the immediate area of hazardous objects, guide the patient to the ground if standing to prevent falls, and place padding under the head. Physical restraint should be avoided as it risks injury to both the patient and the responder. The persistent myth of placing objects in the mouth to prevent tongue swallowing should be actively discouraged as it serves no purpose and risks dental injury, aspiration, or harm to the person attempting the maneuver. Timing the seizure duration provides critical information for medical decision-making regarding the need for emergency treatment.

Once the convulsive phase of the seizure terminates, the patient should be positioned on their side in the recovery position to protect the airway and allow secretions to drain. The postictal period is characterized by confusion, fatigue, and sometimes agitation, during which the patient should be monitored and reassured until returning to baseline mental status. Todd's paralysis describes focal weakness following a seizure, typically corresponding to the brain region involved in seizure onset, and resolves spontaneously over minutes to hours. Prolonged confusion exceeding thirty minutes or failure to return to baseline mental status should raise concern for ongoing non-convulsive seizure activity requiring emergency evaluation and electroencephalography.

Emergency department evaluation following a seizure includes detailed history from the patient and witnesses, physical examination with attention to neurological findings and evidence of injury, and directed laboratory testing. Glucose, serum electrolytes including sodium, and toxicology screening address common precipitants of provoked seizures. In patients on antiseizure medications, drug levels help assess compliance and adequacy of dosing. Neuroimaging with computed tomography is indicated for first seizures, focal features suggesting a structural lesion, persistent neurological deficits, significant head trauma, or suspected central nervous system infection. Electroencephalography is typically arranged as an outpatient study unless status epilepticus or ongoing seizure activity is suspected.

Disposition following seizure evaluation depends on the clinical context and findings. Patients with known epilepsy experiencing a typical seizure in the context of an identifiable precipitant such as missed medications, sleep deprivation, or alcohol use can often be discharged with medication adjustment and close outpatient follow-up. First seizures with normal evaluation require discussion of recurrence risk and shared decision-making regarding treatment initiation versus observation with outpatient electroencephalography and neuroimaging. Abnormal findings on neurological examination, computed tomography, or laboratory studies generally warrant admission for further evaluation. Status epilepticus requires intensive care unit admission for ongoing monitoring and management.

<image>Panel A: Illustrated guide to bystander seizure first aid showing positioning, timing, recovery position, and common misconceptions to avoid. Panel B: Postictal phenomena table describing confusion, Todd's paralysis, headache, and timeframes for typical resolution. Panel C: Emergency department evaluation algorithm showing history, examination, laboratory, and imaging indications. Panel D: Disposition decision flowchart based on clinical scenario including known epilepsy with typical seizure, first seizure, and concerning features requiring admission.</image>

Summary

• Seizure represents abnormal neuronal activity; epilepsy is defined as two or more unprovoked seizures or one seizure with high recurrence risk
• Focal seizures arise from one hemisphere and may occur with preserved or impaired awareness
• Generalized seizures include tonic-clonic, absence, myoclonic, tonic, and atonic types engaging bilateral networks from onset
• Juvenile myoclonic epilepsy presents in adolescence with morning myoclonic jerks, generalized tonic-clonic seizures, and requires lifelong treatment
• First unprovoked seizure carries approximately forty percent two-year recurrence risk, higher with abnormal EEG or MRI
• Psychogenic non-epileptic seizures feature variable movements, eyes closed, prolonged duration, and rapid recovery of alertness
• Carbamazepine, phenytoin, and gabapentin should be avoided in genetic generalized epilepsies as they may worsen seizures
• Valproate has broad-spectrum efficacy but is highly teratogenic and should be avoided in women of childbearing potential
• Status epilepticus exceeding five minutes requires benzodiazepines first-line, then fosphenytoin, valproate, or levetiracetam
• Drug-resistant epilepsy affects thirty percent of patients and warrants evaluation for surgery, neuromodulation, or dietary therapy

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown